A Swedish medical technology company
Senzime develops, manufactures and markets CE- and FDA-cleared patient monitoring systems. The goal is to help eliminate in-hospital complications, and radically reduce healthcare costs related to surgical and high acuity procedures.
Our vision is a world without anesthesia- and respiratory-related complications.
CEO Statement
Growth in the first quarter was clear. Total sales growth was 64 percent, with the U.S. accounting for the largest increase, 109 percent year-over-year, and Europe up 36 percent. Sensor sales increased by 44 percent during the quarter compared to the same period in 2021.
Pia Renaudin
CEO